<DOC>
	<DOCNO>NCT02221648</DOCNO>
	<brief_summary>The scientific aim study investigate efficacy abobotulinumtoxinA ( Dysport - Ipsen Pharmaceuticals ) chronic low back pain . The investigator hypothesis injection Dysport brand botulinum toxin type A erector spinae muscle ( extensor spine ) relieve low back pain anti-spasm analgesic effect botulinum toxin .</brief_summary>
	<brief_title>Investigation Efficacy Botulinum Toxin A ( Dysport ) Chronic Low Back Pain</brief_title>
	<detailed_description>This investigator initiate , randomize , double blind , placebo-controlled study . A total 90 patient enrol study . The study conduct 4 month . It include 4 visit 4 telephone call . Patients chronic low back pain ( &gt; 3 month ) meet inclusion exclusion criterion wish participate study may enrol . Those become enrolled scheduled baseline visit ( Week 0 ) . During baseline visit , subject give official approved consent form read ask question . Participants study also receive copy Dysport Risk Evaluation Mitigation Strategy ( REMS ) statement . After obtain informed consent sign subject , subject randomization Dysport placebo group . The randomizing perform nurse information keep pass-worded computer . Blinding mean neither participant clinical rater know group participant initially assign . Each subject neurological examination fill demographic form complete four rating questionnaire ( appendix II-V ) . These include visual analogue scale pain ( 0 10 ) three quality life questionnaire depict quality life ( American Chronic Pain Association 's Quality Life Scale ) , pain affect ability manage everyday life ( Oswestry Low Back Pain Disability Questionnaire ) , overall physical emotional health ( Short Form-36 ) . Patients receive injection either abobotulinumA ( Dysport ) normal saline . Dysport saline administer paraspinal muscle ( extensor erector spinae ) five level ( L1-L5 ) , regardless pain location . In case unilateral pain , would amount 500 unit total , case bilateral pain , 1000 unit total , Dysport per session . The primary outcome study number patient VAS &lt; 4 ( subtle pain ) week 6 placebo Dysport injection .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Age 1880 , ethnic group , race , sex . Diagnosis chronic low back pain ( long 3 month ) . Pain moderate severe intensity ( VAS 4 high ) . Subjects able read , speak , understand English . Existing significant acute medical condition ( i.e . cardiovascular , endocrine , hematologic , neoplastic , infectious , autoimmune disorder ) . Hypersensitivity botulinum toxin product recipient Allergy albumin . Lactose cow milk protein Infection propose injection site . Pregnancy plan pregnancy ( determined urine pregnancy test ) . The woman childbearing age use reliable mode contraception study period ( abstinence , etc ) . Active breast feeding . Enrollment clinical trial ( currently within past 3 month ) treatment impose protocol . Patients take high dos aminoglycosides drug affect function neuromuscular junction ( anticholinergic , muscle relaxant ) Subjects young 18 year age . Neuromuscularjunction disorder motor neuron disease Amyotrophic Lateral Sclerosis . Evidence acute pathology neuroimaging . Axis I diagnosis determined neurologist psychiatrist . Anesthetic medication within two week corticosteroid injection within 4 week enrollment . Received botulinum toxin injection past 3 month . History low back surgery , evidence acute disc severe lumbar stenosis MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Back</keyword>
	<keyword>Pain</keyword>
	<keyword>Muscle</keyword>
</DOC>